Attention The Medicines Company Investors: The Medicines Company Misled Investors According to a Recently Filed Class Action

   Attention The Medicines Company Investors: The Medicines Company Misled
             Investors According to a Recently Filed Class Action

PR Newswire

SAN DIEGO and PARSIPPANY, N.J., March 3, 2014

SAN DIEGO and PARSIPPANY, N.J., March 3, 2014 /PRNewswire/ --Shareholder
rights law firm Robbins Arroyo LLP announces that an investor of The Medicines
Company (NASDAQ: MDCO) has filed a federal securities fraud class action
complaint in the U.S. District Court for the District of New Jersey. The
complaint alleges that the company and certain of its officers and directors
violated the Securities and Exchange Act of 1934 between February 20, 2013 and
February 12, 2014 (the "Class Period"). Medicines is a global pharmaceutical
company that specializes in providing medical solutions for critical care
patients in acute intensive care hospitals worldwide. 

Robbins Arroyo LLP.

Medicines Is Accused of Misrepresenting the Drug Cangrelor

According to the complaint, shares of Medicines fell on multiple occasions
beginning with an initial decline $1.80 or over 5%, in which Medicines closed
at $32.42 on February 10, 2014, after the release of briefing documents from
the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs
Advisory Committee in advance of the FDA's review of Medicines' drug
application for Cangrelor, a drug intended to prevent blood clots during
heart-artery clearing angioplasty and stenting procedures. The documents
concluded that Cangrelor did not show superiority to Clopidogrel, a competing
drug already approved by the FDA. Moreover, the initial FDA finding disclosed
that the clinical trials sponsored by Medicines were unethically and
inappropriately controlled because the administration of Clopidogrel was
delayed and the dosage of Clopidogrel lowered in the CHAMPION trial which was
designed to compare the efficacy of Cangrelor to Clopidogrel. Shares of
Medicines further declined $3.82, or over 11.5%, to close at $29.28 on
February 13, 2014, after the FDA advisory panel voted 7-2 against the approval
of Cangrelor.

The complaint further alleges that Medicines made materially false and
misleading statements regarding the company's business, operational,
compliance policies and improperly touted Cangrelor despite the fact that the
drug did not show superiority to Clopidogrel and that the company's CHAMPION
clinical trials were unethically and inappropriately administrated.

Medicines Shareholders Are Encouraged to Contact Shareholder Rights Law Firm
Robbins Arroyo

If you invested in Medicines and would like to discuss your shareholder
rights, please contact attorney Darnell R. Donahue at (800) 350-6003,
DDonahue@robbinsarroyo.com, or via the information form on the firm's
shareholder rights blog:
www.robbinsarroyo.com/shareholders-rights-blog/the-medicines-company

Robbins Arroyo LLP is a nationally recognized leader in securities litigation
and shareholder rights law. The firm represents individual and institutional
investors in shareholder derivative and securities class action lawsuits, and
has helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested.

Attorney Advertising.Past results do not guarantee a similar outcome.

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

Photo - http://photos.prnewswire.com/prnh/20130103/MM36754LOGO

SOURCE Robbins Arroyo LLP

Website: http://robbinsumeda.com
 
Press spacebar to pause and continue. Press esc to stop.